Thyroid Eye Disease (TED) Market Report 2026

Thyroid Eye Disease (TED) Market Overview

• Thyroid Eye Disease (TED) market size has reached to $2.29 billion in 2025 • Expected to grow to $3.12 billion in 2030 at a compound annual growth rate (CAGR) of 6.3% • Growth Driver: Thyroid Disorders And Their Influence On The Market Dynamics • Market Trend: Amgen's TEPEZZA (Teprotumumab)A Breakthrough In Thyroid Eye Disease Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Thyroid Eye Disease (TED) Market?

Thyroid eye disease (TED), also known as Graves' Orbitopathy, is an autoimmune condition characterized by inflammation and swelling of the tissues around the eyes, often associated with thyroid disorders. TED can cause symptoms such as bulging eyes, double vision, and eye pain. The main treatment types of thyroid eye disease (TED) are medical, surgical, and a combination of medical and surgical approaches. Medical treatment of thyroid eye disease (TED) typically involves the use of corticosteroids, immunosuppressive drugs, and biologic therapies to reduce inflammation, control symptoms, and prevent disease progression. It is tailored based on the disease severity, which can be classified into mild, moderate, and severe stages. Drugs used for treatment fall into different categories, including biologics, small molecules, and others. It is available in various routes of administration options, including oral, intravenous, and subcutaneous delivery methods and are used by several end users such as hospitals, clinics, and others.

What Is The Thyroid Eye Disease (TED) Market Growth Forecast?

The thyroid eye disease (ted) market size is expected to see strong growth in the next few years. It will grow to $3.12 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing adoption of novel biologics such as teprotumumab, rising investments in autoimmune disease research, expansion of minimally invasive surgical options, growing focus on quality-of-life outcomes, increasing demand for personalized ted therapies. Major trends in the forecast period include increasing adoption of targeted biologic therapies, rising use of combination treatment approaches, growing focus on early disease intervention, expansion of specialized ophthalmic care, enhanced patient-centered treatment models.

Global Thyroid Eye Disease (TED) Market Segmentation

1) By Treatment Type: Medical, Surgical, Combination Of Medical And Surgical 2) By Disease Severity: Mild, Moderate, Severe 3) By Drug Type: Biologics, Small Molecules, Other Drug Types 4) By Route Of Administration: Oral, Intravenous, Subcutaneous 5) By End User: Hospitals, Clinics, Other End Users Subsegments: 1) By Medical: Corticosteroids, Teprotumumab, Antithyroid Medications 2) By Surgical: Orbital Decompression Surgery, Eyelid Surgery, Strabismus Surgery 3) By Combination Of Medical and Surgical: Combination of Corticosteroids and Orbital Decompression, Combination of Teprotumumab and Eyelid Surgery

What Is The Driver Of The Thyroid Eye Disease (TED) Market?

Rising thyroid disorders are expected to propel the growth of the thyroid eye disease (TED) market going forward. Thyroid disorders are medical conditions that affect the function of the thyroid gland, leading to imbalances in hormone production and resulting in conditions such as hypothyroidism, hyperthyroidism, goiter, and thyroid eye disease. Rising thyroid disorders are driven by factors such as increased iodine intake, autoimmune conditions, genetic predisposition, and greater awareness leading to improved diagnostic rates. Thyroid Eye Disease (TED) contributes to the rise in thyroid disorder cases, as it is a common and serious complication of Graves' disease, increasing the overall burden and awareness of thyroid-related conditions. For instance, in May 2024, according to the Canadian Cancer Society, a Canada-based non-profit, community-based organization, in 2024, an estimated 6,600 new cases of thyroid cancer are expected to be diagnosed in Canada, with approximately 280 fatalities projected. Therefore, rising thyroid disorders are driving the growth of the thyroid eye disease (TED) industry.

Key Players In The Global Thyroid Eye Disease (TED) Market

Major companies operating in the thyroid eye disease (ted) market are Viridian Therapeutics Inc, Tourmaline Bio Inc, Sling Therapeutics Inc, Immunovant Inc, Hoffmann‑La Roche AG, H Lundbeck A S, Alumis Inc, Changchun GeneScience Pharmaceutical Co Ltd, Minghui Pharmaceutical Inc, Amgen Inc, Crinetics Pharmaceuticals Inc, Ollin Biosciences Inc, Lycia Therapeutics Inc, Inflammasome Therapeutics Inc, Novartis Pharmaceuticals Corp, AdvanceCOR Inc, Worg Pharmaceuticals Inc, AV7 Limited, EVOQ Therapeutics Inc, ValenzaBio Inc, Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Sanofi SA, Alexion Pharmaceuticals Inc, Septerna Corporation

Global Thyroid Eye Disease (TED) Market Trends and Insights

Major companies operating in the thyroid eye disease (TED) market are focusing on innovative products, such as monoclonal antibody therapies, to develop more effective, targeted treatments that reduce inflammation, improve proptosis, and enhance overall patient outcomes. Monoclonal antibody therapies are treatments that use laboratory-made antibodies designed to mimic the immune system’s ability to target and neutralize specific pathogens or abnormal cells. For instance, in September 2024, Amgen Inc., a US-based biotechnology company, announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved TEPEZZA (teprotumumab) for treating active thyroid eye disease (TED), a rare and potentially vision-threatening autoimmune disorder. It is the first and only FDA-approved therapy specifically for TED, offering a targeted treatment that helps reduce inflammation, swelling, and other debilitating symptoms associated with the disease. This approval is particularly important for patients in Japan, as it provides a new, effective option to manage TED, a rare and progressive condition that causes debilitating eye bulging, vision problems, and eye pain.

What Are Latest Mergers And Acquisitions In The Thyroid Eye Disease (TED) Market?

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for an undisclosed amount. With this acquisition, Amgen aims to strengthen its rare and inflammatory disease portfolio by leveraging Horizon’s key therapies, expanding global reach, and accelerating innovation for long-term growth. Horizon Therapeutics plc is an Ireland-based company that specializes in rare autoimmune and inflammatory diseases.

Regional Outlook

North America was the largest region in the thyroid eye disease (TED) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Thyroid Eye Disease (TED) Market?

The thyroid eye disease (TED) market includes revenues earned by entities by providing services such as diagnosis services, pharmaceutical services, surgical services, support, and counseling services and related products including thyroid hormone replacement therapy, immunosuppressive drugs, surgical products, and devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Thyroid Eye Disease (TED) Market Report 2026?

The thyroid eye disease (ted) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the thyroid eye disease (ted) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.